Download PDF
Thromb Haemost 2006; 96(05): 690-691
DOI: 10.1160/TH06-08-0419
Case Report
Schattauer GmbH

Pulmonary embolism associated with olanzapine

Ian del Conde
1   Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
,
Samuel Z. Goldhaber
1   Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
2   Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
› Author Affiliations
Further Information

Publication History

Received 01 August 2006

Accepted after revision 18 September 2006

Publication Date:
01 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I4-18.
    PubMedGoogle Scholar
  • 2 Piazza G, Goldhaber SZ. Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation 2006; 114: e28-e32.
    CrossrefPubMedGoogle Scholar
  • 3 Schoepf UJ, Kucher N, Kipfmueller F. et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-80.
    CrossrefPubMedGoogle Scholar
  • 4 Scridon T, Scridon C, Skali H. et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005; 96: 303-5.
    CrossrefPubMedGoogle Scholar
  • 5 Toki S, Morinobu S, Yoshino A. et al. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. J Clin Psychiatry 2004; 65: 1576-7.
    CrossrefPubMedGoogle Scholar
  • 6 Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23.
    CrossrefPubMedGoogle Scholar
  • 7 Walker AM, Lanza LL, Arellano F. et al. Mortality in current and former users of clozapine. Epidemiology 1997; 08: 671-7.
    CrossrefPubMedGoogle Scholar
  • 8 Hagg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003; 18: 299-300.
    CrossrefPubMedGoogle Scholar
  • 9 Liperoti R, Pedone C, Lapane KL. et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165: 2677-82.
    CrossrefPubMedGoogle Scholar
  • 10 Boullin DJ, Woods HF, Grimes RP. et al. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol 1975; 02: 29-35.
    CrossrefPubMedGoogle Scholar
  • 11 Wallaschofski H, Eigenthaler M, Kiefer M. et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003; 23: 479-83.
    CrossrefPubMedGoogle Scholar
  • 12 Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990; 27: 863-70.
    CrossrefPubMedGoogle Scholar
  • 13 Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-6.
    CrossrefPubMedGoogle Scholar
  • 14 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
    CrossrefPubMedGoogle Scholar
  • 15 Brandao LR, Williams S, Kahr WH. et al. Exerciseinduced deep vein thrombosis of the upper extremity. 1. Literature review. Acta Haematol 2006; 115: 214-20.
    CrossrefPubMedGoogle Scholar
  • 16 Arnone D, Hansen L, Davies G. Pulmonary embolism and severe depression. Am J Psychiatry 2002; 159: 873-4.
    CrossrefPubMedGoogle Scholar
  • 17 Hamanaka S, Kamijo Y, Nagai T. et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004; 68: 850-2.
    CrossrefPubMedGoogle Scholar